We are pleased to announce that, effective 24 November 2020, Fidelio Capital AB (“Fidelio”) has completed the acquisition of Premune AB’s (“Premune”) shares in Nextmune.

Through the transaction, Fidelio will increase its ownership in Nextmune and become the majority owner. Nextmune is a leading company within specialty pharmaceuticals for companion animals with sales in over 75 markets worldwide.

With Fidelio as the majority owner, Nextmune will have the support and resources to continue to invest in innovation and R&D and to broaden its product portfolio. The transaction will not lead to any operational changes in the company, which will continue to run in the same way as today.

Fidelio looks forward to continuing to support Nextmune on its journey to improve the quality of life for companion animals around the world.